Celltrion, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Celltrion, Inc. – Product Pipeline Review – 2016’, provides an overview of the Celltrion, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Celltrion, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Celltrion, Inc.

The report provides overview of Celltrion, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Celltrion, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Celltrion, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Celltrion, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Celltrion, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Celltrion, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Celltrion, Inc. Snapshot 5

Celltrion, Inc. Overview 5

Key Information 5

Key Facts 5

Celltrion, Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Celltrion, Inc. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Celltrion, Inc. - Pipeline Products Glance 11

Celltrion, Inc. - Late Stage Pipeline Products 11

Pre-Registration Products/Combination Treatment Modalities 11

Phase III Products/Combination Treatment Modalities 12

Celltrion, Inc. - Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Celltrion, Inc. - Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

Celltrion, Inc. - Drug Profiles 16

rituximab biosimilar 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

trastuzumab biosimilar 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

CTP-27 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

adalimumab biosimilar 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

bevacizumab biosimilar 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

cetuximab biosimilar 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

CTP-26 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

etanercept biosimilar 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

palivizumab biosimilar 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

CTP-19 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

CTP-24 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

CTP-25 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Celltrion, Inc. - Pipeline Analysis 30

Celltrion, Inc. - Pipeline Products by Target 30

Celltrion, Inc. - Pipeline Products by Route of Administration 31

Celltrion, Inc. - Pipeline Products by Molecule Type 32

Celltrion, Inc. - Pipeline Products by Mechanism of Action 33

Celltrion, Inc. - Recent Pipeline Updates 34

Celltrion, Inc. - Dormant Projects 36

Celltrion, Inc. - Company Statement 37

Celltrion, Inc. - Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Tables

List of Tables

Celltrion, Inc., Key Information 5

Celltrion, Inc., Key Facts 5

Celltrion, Inc. – Pipeline by Indication, 2016 7

Celltrion, Inc. – Pipeline by Stage of Development, 2016 9

Celltrion, Inc. – Monotherapy Products in Pipeline, 2016 10

Celltrion, Inc. – Pre-Registration, 2016 11

Celltrion, Inc. – Phase III, 2016 12

Celltrion, Inc. – Phase II, 2016 13

Celltrion, Inc. – Preclinical, 2016 14

Celltrion, Inc. – Discovery, 2016 15

Celltrion, Inc. – Pipeline by Target, 2016 30

Celltrion, Inc. – Pipeline by Route of Administration, 2016 31

Celltrion, Inc. – Pipeline by Molecule Type, 2016 32

Celltrion, Inc. – Pipeline Products by Mechanism of Action, 2016 33

Celltrion, Inc. – Recent Pipeline Updates, 2016 34

Celltrion, Inc. – Dormant Developmental Projects,2016 36

Celltrion, Inc., Subsidiaries 38

List of Figures

List of Figures

Celltrion, Inc. – Pipeline by Top 10 Indication, 2016 7

Celltrion, Inc. – Pipeline by Stage of Development, 2016 9

Celltrion, Inc. – Monotherapy Products in Pipeline, 2016 10

Celltrion, Inc. – Pipeline by Target, 2016 30

Celltrion, Inc. – Pipeline by Route of Administration, 2016 31

Celltrion, Inc. – Pipeline by Molecule Type, 2016 32

Celltrion, Inc. – Pipeline Products by Mechanism of Action, 2016 33

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports